The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | New targets in relapsed/refractory multiple myeloma patients
Dr Sagar Lonial, MD from Emory University, Atlanta, USA, updates us on treatments for patients with relapsed/refractory myeloma from the European Hematology 2017 in Madrid, Spain. Despite exciting advances, we are still seeing lots of patients in this category. Sagar tells us about the new targets that are very important for these patients, including XPO1 targeted by selinexor, PD1 partnered with IMiDs, CAR-T cells and BCMA.
